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Abstract
Background: Chronic total occlusion percutaneous coronary intervention (CTO-PCI) can improve angina and left
ventricular ejection fraction (LVEF). These benefits were not assessed in populations with heart failure with reduced
ejection fraction (HFrEF). We studied the effect of CTO-PCI on left ventricular function and clinical parameters in
patients with HFrEF.
Methods: Using cardiovascular magnetic resonance (CMR), we studied 29 patients with HFrEF and evidence of
viability and/or ischemia in the territory supplied by a CTO who were successfully treated with CTO-PCI. In patients
with multi-vessel disease, non-CTO PCI was also performed. Imaging parameters, clinical status, and brain natriuretic
peptide (BNP) levels were evaluated before and 6 months after CTO-PCI.
Results: A decrease in left ventricular end-systolic volume (160 ± 54 ml vs. 143 ± 58 ml; p = 0.029) and an increase
in LVEF (31.3 ± 7.4 % vs. 37.7 ± 8 %; p < 0.001) were observed. There were no differences in LVEF improvement between
patients who underwent non-CTO PCI (n = 11) and those without this intervention (n = 18); (p = 0.73). The number of
segments showing perfusion defects was significantly reduced (0.5 ± 1 vs. 0.2 ± 0.5; p = 0.043). Angina (p = 0.002) and
NYHA functional class (p = 0.004) improved, and BNP levels decreased (p = 0.004) after CTO-PCI.
Conclusions: In this group of patients with HFrEF showing CMR evidence of viability and/or ischemia within the
territory supplied by the CTO, an improvement in ejection fraction, left ventricular end-systolic volume and ischemia
burden was observed after CTO-PCI. Clinical and laboratory parameters also improved.
Trial registration: ClinicalTrials.gov NCT02570087. Registered 6 October 2015.
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Background
A chronic total occlusion (CTO) is defined as a coronary
obstruction with thrombolysis in myocardial infarction
(TIMI) grade 0 flow that persists for at least 3 months [1].
This type of lesions can be found in up to 50 % of patients
with significant coronary disease on angiography [2]. CTO
percutaneous coronary intervention (PCI) is performed
infrequently likely due to technical complexity, the poten-
tial for major periprocedural complications, the relatively
low procedural success rates and controversial data re-
garding the clinical benefit [3, 4]. According to consensus
documents CTO-PCI should be considered in the pres-
ence of symptoms (or objective evidence of a large region
of ischemia/viability) when the myocardium supplied by
the CTO is viable, the likelihood of success is >60 % and
the anticipated major complication rate is low [5, 6].
Potential CTO-PCI benefits are ischemia reduction, an-
gina relief, and improved left ventricular ejection function
(LVEF) and long-term survival [7–18]. However, these
data come from studies enrolling patients with preserved
LVEF, where clinical benefits of myocardial revasculariza-
tion are potentially lower. Thus, the present study aimed
to assess whether CTO-PCI in patients with chronic heart
failure and reduced ejection fraction (HFrEF) is associated
with an improvement in LVEF, angina status, New York
Heart Association (NYHA) functional class for dyspnea
(NYHA I-IV) and brain natriuretic peptide (BNP) levels.
Methods
Study population
We prospectively collected data from consecutive pa-
tients referred to our institution for invasive coronary
angiography from January 2011 to June 2013, selecting
those with at least one CTO and LVEF ≤40 % measured
by echocardiography, gated-SPECT or contrast ventricu-
lography (n = 256). A CTO was defined as an occlusion
of at least 3 months of duration based on a previous
angiogram showing the occluded vessel or clinical data
on previous coronary ischemic events potentially related
to a coronary occlusion. Patients who did not meet any
of the exclusion criteria, detailed below, underwent car-
diovascular magnetic resonance (CMR) study (Fig. 1).
CTO recanalization was attempted in those with LVEF
≤40 % confirmed by CMR and with evidence of myocar-
dial viability and/or ischemia in at least two contiguous
segments subtended by the CTO (n = 39). The main rea-
sons for exclusion were a lack of ischemia and myocar-
dial viability in at least two contiguous CTO dependent
myocardial segments by CMR (n = 25; 12 %), the pres-
ence of a pacemaker or an implantable cardioverter de-
fibrillator (n = 25; 12 %) and surgical or percutaneous
revascularization during the candidacy evaluation with
no chance to perform basal assessments (n = 25; 12 %).
The final study population included the 32 patients with
successful CTO-PCI (82 % success rate).
Exclusion criteria
Clinical criteria for exclusion were women of childbear-
ing age or pregnant, patients younger than 18 or older
than 80 years, contraindications for CMR (pacemakers,
implantable cardioverter defibrillators, claustrophobia
and cochlea implants), or hospital admission within the
previous 90 days due to decompensated heart failure,
myocardial infarction or unstable angina. Additional cri-
teria were iodine contrast or gadolinium allergy, aspirin
or clopidogrel allergy, asthma, NYHA IV, chronic kidney
disease with serum creatinine levels ≥2.5 mg/dl or
glomerular filtration rate ≤30 ml/min/1.73 m2, severe
valvulopathy, indication for coronary artery bypass sur-
gery, heart transplantation waiting list, high comorbid-
ity, liver cirrhosis, evidence of active bleeding or high
risk of bleeding, follow-up not feasible, noncompliance
with medical treatment or life expectancy shorter than
12 months.
Technical criteria for exclusion were CTO distal ves-
sel not visible through collateral circulation, CTO distal
vessel diameter <2 mm or absence of acceptable vascu-
lar access.
Fig. 1 Flow chart of patient inclusion. Abbreviations: CABG, coronary
artery bypass graft; CMR, cardiovascular magnetic resonance; CTO,
chronic total occlusion; ICD, implantable cardioverter defibrillator;
LVEF, left ventricular ejection fraction; PCI, percutaneous
coronary intervention
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CMR studies
All CMR studies (baseline and 6-month follow-up, mean
duration of 45 min) were performed using a General Elec-
tric Signa HDxt 1.5-T scanner equipped with an 8-channel
coil and cardiac-dedicated software. Perfusion studies
were conducted using a gradient-echo turbo-field se-
quence prescribed in the left ventricular short-axis orien-
tation, at the basal, mid-ventricular and apical levels after
4 min of intravenous administration of adenosine (Atepo-
din®) at a dose of 140 mcg/kg/min and simultaneous
administration of 0.1 mmol/kg of gadobutrol (Gadovist®,
Bayer Hispania) at 5 ml/s rate. Functional and volumetric
assessment of the left ventricle (LV) was conducted by
conventional Steady State Free Precession (SSFP) cine se-
quence, prescribed in sequential short-axis slices, and
encompassing the entire LV as well as the 2-, 3-, and 4-
chamber views. Typical temporal and in-plane spatial
resolution of these images was 40 ms and 1.4 × 1.4 mm,
respectively. Rest perfusion images were obtained at least
10 min after the stress perfusion study using the same se-
quence, location, and contrast injection protocol. At
10 min post-administration of the gadolinium dose for the
rest perfusion study, late gadolinium-enhancement (LGE)
images were obtained using a segmented inversion-
recovery spoiled gradient echo sequence in the same loca-
tion and identical spatial resolution as the cine images.
Image analysis
In order to calculate LVEF, LV mass and left ventricular
end-systolic (LVESV) and end-diastolic (LVEDV) vol-
umes, the endocardial and epicardial borders were
manually traced at end-systole and end-diastole in the
cine short-axis images using a dedicated software pack-
age (ReportCard, GE). In addition, infarct size was quan-
tified by planimetry of enhanced areas on the stack of
short-axis images. Regional wall motion analysis was
performed by visual grading of the cine images accord-
ing to the 17-segment model proposed by the American
Heart Association [19] as follows: 0 = normal function,
1 = mild or moderate hypokinesia, 2 = severe hypokine-
sia, 3 akinesia, 4 = dyskinesia. In myocardial perfusion
images, the presence and extent, or absence of a perfu-
sion defect, defined as an evident and maintained hypo-
perfusion in more than 50 % of the segment seen in the
stress images but not in the rest images, were evaluated
by visual analysis of myocardial contrast uptake accord-
ing to a 16-segment model (excluding the 17th seg-
ment) (Fig. 2). The presence and transmural extent of
LGE was graded in every segment using a 5-point scor-
ing system: absence of LGE = 0, <25 % transmural ex-
tent = 1, 26 %–50 % = 2, 51 %–75 % = 3 and >75 % = 4.
Any segment graded ≤2 was considered viable [20].
Image analysis pre and post-PCI was performed by two
Fig. 2 CMR study before PCI in a patient with a CTO in the mid-LAD coronary artery and no other significant coronary stenosis, but a history of
previous inferior ST-elevation myocardial infarction with mid RCA stent implantation. a Stress perfusion images showing an inducible defect in
mid-apical anterior and anteroseptal segments (white arrow). b Resting perfusion images showing no perfusion defects. c LGE study showing
transmural enhancement in mid-inferior segment (>75 % transmural extension) (white arrow). Absence of enhancement in basal, mid, and apical
antero-septal segments
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independent experienced operators masked to the pa-
tient’s coronary anatomy and to PCI results; disparities in
their evaluation were resolved by consensus with a third
independent operator. Appropriate allocation between the
involved myocardial segments and the correspondent cor-
onary anatomy in each case was evaluated according to
previously reported criteria [21].
Revascularization strategy
Unilateral or bilateral femoral puncture was the vascular
access of choice. Antegrade approach was the choice in
all cases, with retrograde approach being used in some
re-attempts. With the intention being complete anatom-
ical revascularization, non-CTO PCI was performed
when myocardial viability was detected. In the presence
of multivessel disease and appropriate distal beds for
surgical revascularization, CTO-PCI was the first sched-
uled interventional procedure enabling patient referral
to surgical revascularization in case of failure. If the pa-
tient was not a candidate for surgical revascularization,
any non-occlusive stenosis was treated first, leaving
CTO-PCI as the last procedure. The average time be-
tween PCI procedures was 4 weeks. Drug-eluting stents
were implanted when feasible. Successful CTO-PCI was
defined as the restoration of TIMI grade 3 flow with re-
sidual stenosis of less than 30 % and no immediate
angiographic complications.
Clinical follow-up and BNP levels
Clinical follow-up visits were scheduled at 30 days,
3 months and 6 months after CTO-PCI. Angina status
and NYHA functional class for dyspnea were assessed
before and 6 months after successful CTO-PCI. Plasma
levels of BNP were also obtained before the procedure
and at follow-up using ADVIA Centaur® BNP chemilu-
minescence immunoassay and autoanalyzer (Siemens
Healthcare Diagnostics). All patients included in the
study had been on guidelines recommended medication
for HFrEF for at least 3 months before CTO-PCI pro-
cedure. Furthermore, during the 6-month study period
there were no changes in prescribed medical treatment
for angina or heart failure according to data collected at
each follow-up visit, and no cardiac resynchronization
therapy devices were implanted.
Statistical analysis
In the descriptive analysis, categorical variables are pre-
sented as n and percentage. Continuous variables are
presented as mean ± SD when normally distributed, and
median (interquartile range [IQR]) otherwise. Group
differences were evaluated using chi-square or Fisher
exact test for categorical variables. Student t test and
Mann-Whitney rank sum test were used for continuous
variables. Comparisons between pre- and post-PCI
clinical parameters, BNP levels, and CMR studies were
performed by paired t-tests, Wilcoxon signed rank or
McNemar test, as appropriate. CMR regional contract-
ility and perfusion defect analysis were repeated, taking
into account only those segments within the myocar-
dium subtended by a CTO considered for PCI. Add-
itionally, the difference in LVEF between baseline and
6-month follow-up CMR studies was analyzed in a
mixed-effects multivariate model adjusted for baseline
characteristics and non-CTO PCI procedure. A two-
tailed p < 0.05 was considered significant. Statistical
analysis was performed using SPSS version 13.0 (SPSS,
Inc.; Chicago, Illinois, USA).
Results
Study population
In total, 32 patients with successful CTO-PCI were in-
cluded in the study. Baseline demographic and clinical
characteristics of this population are shown in Table 1.
PCI data
Baseline angiographic characteristics of the 32 patients
with successful CTO-PCI are shown in Table 2. Most of
the patients had multi-vessel disease with a single CTO.
The most common location of occlusions was left anter-
ior descending artery (LAD), followed by right coronary
artery (RCA) and left circumflex artery (LCX). A total of
34 CTOs were recanalized, 16 in LAD, 10 in RCA, and
8 in LCX. Within the group of patients with more than
one CTO, 7 of these CTO were not recanalized because
of a lack of ischemia and myocardial viability in the ter-
ritory subtended by the occluded vessel, according to
study criteria. Two CTO-PCI procedures were required
in 4 patients, two of them with retrograde approach.
Drug-eluting stents were implanted in 94 % of successful
CTO-PCIs, with a mean of 2 ± 1.1 stents/lesion (range
0–5) and a stent length of 47 mm ± 27 (range 0–116).
Eleven patients (34 %) underwent non-CTO PCI.
Complete anatomical revascularization rate was 91 %.
No procedural complications (coronary perforation, car-
diac tamponade or emergent cardiac surgery) were ob-
served in any patient undergoing CTO-PCI attempt. No
patient died, and none had Q wave myocardial infarction
or stroke during the hospital phase. Patients were pre-
scribed aspirin indefinitely and clopidogrel 75 mg daily
for at least 12 months after successful CTO-PCI.
CMR findings
Myocardial viability in at least two contiguous CTO
dependent myocardial segments was present in all the
included patients. Only five patients (16 %) had ischemia
in two or more myocardial segments subtended by a
CTO (mean number of ischemic segments subtended by
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a CTO in the study population was 0.6 ± 1.4 per patient
[range 0–6]).
At 6-month follow-up, CMR studies were performed
in 29 patients (two patients refused the repeat CMR
and 1 patient suffered sudden cardiac death before
follow-up CMR). A significant decrease in LVESV was
found (160 ± 54 ml vs. 143 ± 58 ml; p = 0.029), along
with a 6.4-point improvement in LVEF (31.3 ± 7.4 % vs.
37.7 ± 8 %; p < 0.001) (Table 3). No significant changes
in LVEDV (230 ± 64 ml vs. 221 ± 58 ml; p = 0.25) and
necrotic mass (22 ± 12 g vs. 20.4 ± 10.6 g; p = 0.13) were
seen after successful CTO-PCI. There was no difference
in LVEF improvement between the 11 patients (38 %)
who underwent associated non-CTO PCI and the 18
patients (62 %) without this intervention (5.9 ± 6.7 [IQR
0–11] vs. 6.9 ± 8.2 [IQR 2–11] points; p = 0.73). The im-
provement in LVEF after successful CTO-PCI persisted
in a mixed-effects multivariate model adjusted for baseline
ACEF score and non-CTO PCI (p < 0.001). The degree of
LVEF improvement was not significantly modified by
baseline parameters such as LVEF (8.5 ± 8.9 [IQR 2–13.6]
vs. 4.4 ± 5 [IQR 0–8.2] points; p = 0.14), history of hyper-
tension (4.8 ± 6.4 [IQR 0–11] vs. 9.3 ± 8.3 [IQR 5–13.6]
points; p = 0.12), hypercholesterolemia (8.3 ± 8.3 [IQR
3–11] vs. 4.8 ± 6.3 [IQR 0.5–8.5] points; p = 0.21) or
diabetes (5.3 ± 6.7 [IQR 1–11] vs. 8.8 ± 8.5 [IQR 6–9]
points; p = 0.25), or treatment with angiotensin-converting
enzyme inhibitors/angiotensin receptor blockers (7.9 ± 7
[IQR 3–13.6] vs. 6 ± 7.5 [IQR 1–11] points; p = 0.57), beta
Table 2 Baseline angiographic characteristics of the study group
Successful CTO-PCI
n = 32
Vessels with CTO 41
1 24 (75 %)
2 7 (22 %)
3 1 (3 %)
CTO distribution 41
LAD 17 (41 %)
RCA 15 (37 %)
LCX 9 (22 %)
Coronary arteries with significant stenosis
1 5 (16 %)
2 19 (59 %)
3 8 (25 %)
Rentop score 1.7 ± 1.3
2 (0–3)
Syntax score 22.7 ± 10.2
21.5 (15.5–29.5)
Values are given as mean ± standard deviation, median (interquartile range)
and n (%). CTO indicates chronic total occlusion; LAD left anterior descending
artery, LCX left circumflex artery, RCA right coronary artery




Age (y) 59 ± 10.2
Female 8 (21 %)
Hypertension 15 (47 %)
Hyperlipidemia 17 (53 %)
Diabetes 10 (31 %)
HbA1C (%) 7 ± 1.7
History of smoking
No 13 (41 %)
Yes 11 (34 %)
Current smoker 8 (25 %)
Creatinine (mg/dl) 1 ± 0.2
GFR (MDRD-4; ml/min) 58 ± 5.2
Previous stroke 1 (3 %)
Peripheral arterial vasculopathy 8 (25 %)
LVEF (%) by echocardiography 30 ± 6.9
30 (25–35.8)
ACEF score* 2 ± 0.8
2 (1.4–2.7)
Angina 11 (34 %)
NYHA functional class
1 0
2 23 (72 %)
3 9 (28 %)
Atrial fibrillation/Atrial flutter 1 (3 %)
Previous MI 18 (56 %)
Previous STEMI 14 (44 %)
Q waves 19 (59 %)
Previous PCI 11 (34 %)
Previous CABG 4 (13 %)
ACEi/ARB 26 (81 %)
Beta blockers 29 (91 %)
Aldosterone receptor antagonists 14 (44 %)
Diuretics 16 (50 %)
Digoxin 1 (3 %)
Statin 30 (94 %)
Values are given as mean ± standard deviation, median (interquartile range)
and n (%). ACEi indicates angiotensin-converting enzyme inhibitor; ARB angiotensin
receptor blocker, CABG coronary artery bypass graft, GFR glomerular filtration rate,
HbA1C glycosylated hemoglobin, LVEF left ventricular ejection fraction,
MI myocardial infarction, NYHA New York Heart Association functional class,
PCI percutaneous coronary intervention, STEMI ST-elevation
myocardial infarction
*ACEF score: age (y)/ejection fraction (%) +1 (if serum creatinine >2 mg/dL)
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blockers (2.7 ± 6 [IQR 3–9] vs. 6.8 ± 7.4 [IQR 2–11]
points; p = 0.36) or aldosterone receptor antagonists
(5.2 ± 6.2 [IQR 1–9] vs. 8.1 ± 8.7 [IQR 3.5–12] points;
p = 0.31).
A total of 464 segments were available for perfusion
analysis and 493 for regional contractility. The number of
segments with normal wall motion or mild/moderate
hypokinesia improved after successful CTO-PCI (8.5 ± 4.5
vs. 11.2 ± 3.5; p = 0.001) and the number of segments with
severe hypokinesia, akinesia, or dyskinesia was signifi-
cantly reduced (8.3 ± 4.6 vs. 5.7 ± 3.5; p = 0.002). The
same changes were seen when the analysis was re-
stricted to recanalized CTO-dependent myocardial seg-
ments (Table 4). After successful CTO-PCI, there was
also a significant reduction in the number of segments
showing an inducible perfusion defect in territories
subtended by CTOs (0.5 ± 1 vs. 0.2 ± 0.5; p = 0.043). In
the global analysis including 16 segments per patient, a
trend toward a reduction in the number of ischemic
segments was maintained (1 ± 1.8 vs. 0.3 ± 0.8; p = 0.055).
Clinical follow-up
At 6 months after successful CTO-PCI a significant reduc-
tion, compared to baseline, was observed in the proportion
of patients with angina (34.4 % vs. 3.1 %; p = 0.002) and
in BNP levels (323 ± 657 pg/ml [IQR 60.4–238.2] vs.
123 ± 151 pg/ml [IQR 40.6–154.5]; p = 0.004) (Fig. 3).
Follow-up BNP data were not available in one patient
who died 6 months after the procedure and before
blood test collection. NYHA functional class for dys-
pnea improved significantly, with a higher proportion
of patients in NYHA I and II at follow-up (72 % vs.
100 %; p = 0.004) (Fig. 4).
Discussion
In this study we show that in a small group of patients
with CTO and HFrEF, selected for the presence of via-
bility and/or ischemia in myocardial segments subtended
by the occluded vessel by means of CMR study, a signifi-
cant improvement in LVESV, regional contractility, LVEF
and myocardial ischemia was observed after successful
CTO-PCI.
From a clinical point of view, an improvement in an-
gina and NYHA functional class, along with a decrease
in BNP levels was seen after CTO recanalization.
To our knowledge, this is the first study to date
evaluating the benefits of CTO-PCI in patients with
HFrEF. The proportion of patients with history of pre-
vious myocardial infarction and the high prevalence of
Table 3 Comparison of LVEF, LV volumes, LV mass and LV necrotic mass by CMR before and after successful CTO recanalization
Successful CTO-PCI
n = 29
Pre-PCI Post-PCI Difference p
LVEF (%) Mean 31.3 ± 7.4 Mean 37.7 ± 8 6.4 <0.001
Median (IQR) 32 (26–37) Median (IQR) 39 (35–43)
LVEDV (ml) Mean 230 ± 64 Mean 221 ± 58 −9.1 0.25
Median (IQR) 216 (182–257) Median (IQR) 205 (185–262)
LVESV (ml) Mean 160 ± 54 Mean 143 ± 58 −17 0.03
Median (IQR) 144 (127–194) Median (IQR) 130 (106–166)
LV mass (g) Mean 142 ± 43 Mean 139 ± 47 3.5 0.63
Median (IQR) 132 (107–164) Median (IQR) 128 (108–157)
LV necrotic mass (g) Mean 22 ± 12 Mean 20.4 ± 10.6 −1.6 0.13
Median (IQR) 19.2 (13–30.4) Median (IQR) 18 (12.3–28.7)
CTO indicates chronic total occlusion; IQR interquartile range, LV left ventricle, LVEF left ventricular ejection fraction, LVEDV left ventricular end-diastolic volume,
LVESV left ventricular end-systolic volume, PCI percutaneous coronary intervention
Table 4 Comparison of regional contractility by CMR before and after successful CTO recanalization
Successful CTO-PCI
n = 29
Regional contractility Pre-PCI Post-PCI Difference p
Global Normal or mild-moderate hypokinesia 8.5 ± 4.5 11.2 ± 3.5 2.7 0.001
Severe hypokinesia/akinesia/dyskinesia 8.3 ± 4.6 5.7 ± 3.5 −2.6 0.002
CTO- dependent segments Normal or mild-moderate hypokinesia 2.9 ± 2.2 3.6 ± 2 0.7 0.011
Severe hypokinesia/akinesia/dyskinesia 3.9 ± 1.8 3.3 ± 1.3 −0.62 0.029
Values are given as mean ± standard deviation. CTO indicates chronic total occlusion; PCI percutaneous coronary intervention
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classic cardiovascular risk factors in this cohort are
consistent with previous published data [22, 23]. Im-
provement in angina status after CTO-PCI has also
been shown in previous studies in patients with pre-
served LVEF [7, 8, 12, 16, 18].
CMR is a powerful tool over other modalities to assess
viability in patients with reduced LVEF being considered
for CTO-PCI and to determine improvement in LVEF
after successful CTO-PCI in this population. The CMR
findings in our study partially correlate with those re-
ported by Baks et al. and Kirschbaum et al. [9, 10] Both
of these previous studies, with sample sizes similar to
our cohort, showed a reduction in LVESV and LVEDV
with no significant improvement in LVEF after success-
ful CTO-PCI. It should be noted, however, that inclusion
criteria in both studies differed from our cohort: the via-
bility of CTO-dependent myocardial segments assessed
by CMR was not a criterion, and all patients had pre-
served LVEF. All cases in our cohort had LVEF ≤40 %
and showed evidence of viability by CMR in myocardial
segments subtended by a CTO. In 17 patients with
well-preserved LVEF, Cheng et al. [11] also reported
improvement in wall thickening of myocardial seg-
ments subtended by a successfully recanalized CTO
and no changes in LVEF and LV volumes by CMR. All
three mentioned studies [9–11] showed that the im-
provement in regional wall thickening after a successful
CTO-PCI was indirectly related to the transmurality of
LGE in a myocardial segment. More recently and in
consonance with our findings, Bucciarelli-Ducci et al.
[12] reported a significant improvement in LVESV and
LVEF after successful CTO-PCI in a group of 32 pa-
tients with preserved LVEF showing CMR evidence of
myocardial viability and ischemia. Other than older
studies assessing LVEF with contrast ventriculography
[13, 14], Valenti et al. published the only large study to
Fig. 3 Graph showing a significant reduction in brain natriuretic peptide (BNP) levels after successful CTO-PCI (n = 31)
Fig. 4 Graph showing changes in New York Heart Association
(NYHA) functional class for dyspnea after successful CTO-PCI (n = 32)
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date showing improved LVEF after successful CTO re-
canalization [15]. In their study, 290 patients with vi-
able myocardium in territories supplied by CTO and
most of them with preserved LVEF were evaluated by
Doppler echocardiography before and after the PCI
procedure.
One third of our patients with successful CTO-PCI also
underwent PCI of non-occlusive coronary stenosis. No
differences in the degree of LVEF improvement were seen
when this group was compared with patients who did not
undergo non-CTO PCI, suggesting that changes in LV
function parameters after successful CTO-PCI were de-
rived from CTO recanalization. Baseline patient charac-
teristics such as LVEF, targeted therapies for HFrEF and
the presence of cardiovascular risk factors did not have a
significant impact on the degree of LVEF improvement
after CTO-PCI.
Improvement in myocardial ischemia assessed by CMR
adenosine stress perfusion imaging after successful CTO-
PCI has been previously demonstrated in small series.
Pujadas et al. [7] showed a reduction in the number of
ischemic segments in 33 patients who underwent success-
ful PCI of a single CTO. Similarly, Bucciarelli-Ducci et al.
[12] described a complete or almost complete resolution
of perfusion defect after CTO-PCI along with an increased
myocardial perfusion reserve in the CTO territory. It is
worth mentioning that in both studies LVEF was pre-
served in most of the patients before the PCI procedure
and mean necrotic mass was much lower than in the
present study (6 and 11 g vs. 22 g).
Interestingly, changes in CMR parameters after success-
ful CTO-PCI were associated with an improvement in
NYHA functional class for dyspnea in our study, along
with a significant reduction in BNP levels. These clinical
outcomes had not been previously evaluated in the CTO-
PCI field. Along with LVEF and NYHA functional class,
BNP levels are a prognostic marker in the population with
HFrEF and they can be a useful clinical tool to stratify the
risk of adverse events in this population [24, 25]. Improve-
ment in ischemia burden, LVEF, NYHA functional class
and BNP levels after CTO-PCI in patients with HFrEF
could lead to improved prognosis in this population and
provide a rationale for attempting CTO recanalization
after viability and/or ischemia confirmation in the terri-
tory subtended by the occluded vessel.
Finally, the absence of procedural complications or
any increase in the amount of myocardial necrosis in the
present study may suggest that the CTO-PCI procedure
is safe in selected patients with HFrEF.
This study has several limitations worthy of mention.
The first and main limitation is that this was a non-
randomized study without a predefined control group;
therefore, changes in LV function and volumes or in
clinical parameters cannot directly be attributed to the
CTO-PCI procedure, but may be related to conservative
therapy. The second major limitation is the small sample
size. Third, given the strict patient selection, the study
may not be representative of the whole population with
CTO and HFrEF. Finally, we did not perform a second
angiography at 6 months after PCI in any of the patients.
The major strength of this study is that it is the first report
of CMR assessment of LV function after CTO-PCI to
focus specifically on the important population of patients
with HFrEF. The results derived from this study should be
interpreted cautiously and prospective randomized con-
trolled trials are warranted to validate these findings with
more reliable clinical evidence.
Conclusions
In this group of patients with HFrEF showing CMR evi-
dence of viability and/or ischemia within the territory sup-
plied by the CTO, an improvement in ejection fraction,
left ventricular end-systolic volume and ischemia burden
was observed after CTO-PCI. Clinical and laboratory pa-
rameters also improved.
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